Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-05-13 5:34 pm Unchanged |
2024-03-25 | 13G | Q32 Bio Inc. QTTB |
ARCH Venture Fund VIII L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 3:17 pm Sale |
2023-10-12 | 13G | Scholar Rock Holding Corporation SRRK |
ARCH Venture Fund VIII L.P. | 0 0.000% |
-2,637,617 (Position Closed) |
Filing History |
| 2022-09-20 4:57 pm Purchase |
2022-09-13 | 13D | CODIAK BIOSCIENCES INC CDAKQ |
ARCH Venture Fund VIII L.P. | 8,854,098 24.700% |
5,000,000 (+129.73%) |
Filing History |
| 2022-02-08 3:04 pm Sale |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
ARCH Venture Fund VIII L.P. | 0 0.000% |
-10,735,948 (Position Closed) |
Filing History |
| 2021-02-04 5:11 pm Purchase |
2020-12-31 | 13G | CODIAK BIOSCIENCES INC CDAKQ |
ARCH Venture Fund VIII L.P. | 3,854,098 20.500% |
3,854,098 (New Position) |
Filing History |
| 2021-02-02 5:04 pm Purchase |
2020-12-31 | 13G | Metacrine, Inc. MTCR |
ARCH Venture Fund VIII L.P. | 2,940,503 11.300% |
2,940,503 (New Position) |
Filing History |
| 2021-02-02 5:04 pm Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
ARCH Venture Fund VIII L.P. | 10,735,948 9.000% |
37,339 (+0.35%) |
Filing History |